Adult onset Langerhans cell histiocytosis (LCH) is a rare disorder. Its clinical features have been well described in children, however remain poorly defined in adults. Optimal treatment strategy is still under debate. We have encountered two cases of adult onset LCH, which obtained a durable disease control by combination chemotherapy using prednisone, vinblastine and 6-mercaptopurine. Herein, we report their clinical features together with a review of the current literature.
Introduction
Langerhans cell hisitocytosis (LCH) is characterized by a clonal proliferation of Langerhans cells that predominantly occurs in infants and small children. Patients with localized disease or diseases limited to single organ system have a good prognosis, thus local therapy or close follow-up without therapy would be an appropriate treatment choice. In contrast, multisystem disease with multiple organ involvement carries a poor prognosis requiring therapy with cytotoxic drugs and/or steroids (1) (2) (3) . In one report of 101 children with LCH, the overall survival rate was 79% at 1 year and 71% at 5 years, however, in patients with liver or spleen involvement, 1 year survival was 33% and 5 year survival was 25% (4) .
LCH in adults is extremely rare, therefore, its clinical picture is not fully understood and optimal treatment is not established. Only a few reports describing a series of adult patients with LCH are currently available (5) (6) (7) (8) . We herein report two cases of adult-onset multisystem LCH in Japanese, which obtained a durable disease control by combination chemotherapy together with a review of the current literature.
Case Report

Case 1
A 27-year-old man was admitted to our hospital for the evaluation of multiple lung nodules in August 2007. The patient had noticed the appearance of skin rashes on his forehead since 2004. In 2006, he started complaining of tinnitus and excessive thirst, and frequent urination. Head MRI was performed and a diagnosis of diabetes insipidus (DI) was made. CT scan of the head also showed destruction of his temporal bone leading to the occlusion of his external ear canal. During the work-up, multiple small lung nodules were found on his chest X-ray. Needle biopsy of the temporal bone and transbronchial lung biopsy showed eosinophilic granuloma. He was put on course observation with smoking cessation, however, no clinical improvement was noted. The patient was referred to our hospital for further treatment.
Upon admission, physical examination revealed a mass of 2 cm in his right neck. Skin eruptions of 3 to 5 mm with partial impetigo-like lesions were scattered over his forehead and scalp. Hepatosplenomegaly was not evident. He denied any recent weight loss or persistent fever. The results of blood analysis were all within normal limits except for an increased CRP level (Table 1) . Chest X-ray and CT scan showed multiple small nodules with some emphysematous change in his upper to middle lung fields. CT scan also showed multiple lytic bone lesions in his cranial and pelvic bones and solid masses in the thyroid gland and mediastinum ( Fig. 1 ). Skin biopsy from his forehead showed proliferation of Langerhans cells with indented nucleus; the cells were positive for S-100 and CD1a by immunostaining. Proliferation of lymphocytes and eosinophils was also seen. Electronmicroscopy showed Birbeck granules within the proliferating cells (Fig. 2 ). Based upon these findings, a diagnosis of multi-system LCH was made. He was started on treatment with prednisone and vinblastine, according to the LCH-A1 protocol (briefly, vinblastine 6 mg/m 2 i.v. once a week and oral prednisone 1 mg/ kg daily for four weeks, followed by tapering off of corticosteroids over two weeks period. Continuation therapy was planned with mercaptopurine 30 mg/m 2 orally every day with vinblastine 6 mg/m 2 i.v. every three weeks and prednisone p.o. 1 mg/kg on days 1-5 every three weeks up to six months) (9) . His skin eruptions had completely disappeared by six weeks of treatment. CT scan three months after the beginning of therapy showed improvement in the obstruction of his external ear canal, however, no significant change was seen on other mass lesions including multiple lung nodules. The response to the treatment was considered as AD-better (a state where the patient shows continuous regression of the disease) according to the criteria by the Histiocyte Society (10) .
The patient self-discontinued his treatment at this point, and returned to the clinic one month later, with reappearance of the skin eruption over his forehead. CT scan at the time confirmed no exacerbation of other systemic lesions. He was placed on continuation treatment with 6-mercaptopurine (6-MP), vinblastine and prednisone. After 6 months of continued therapy, he had again obtained ADbetter, where his lung and termporal bone lesions showed further improvement and remained stable, but had not disappeared. After a total of 9 months of treatment, his treatment was stopped as per protocol. One month after discontinuation of therapy, he returned to the clinic again with reappearance of the skin eruptions. No other exacerbation of preexisting lesions was clinically noted. Prednisone 0.5 mg/ kg was restarted, resulting in marked improvement of his skin lesion. He is currently being tapered from his steroid treatment with no recurrence.
Case 2
A 43-year-old woman started complaining of right thigh pain in early 2003. A solitary lytic bone lesion of the right femur was found by CT scan; a needle biopsy was performed that showed proliferation of Langerhans cells that were positive for S-100 by immunostaining, with infiltrating small lymphocytes and eosinophils (Fig. 3) . A diagnosis of LCH was made. Since systemic evaluation showed no other lesions, she was put on observation as an outpatient. In June 2007, she gradually developed pain on her left buttock and back, and was found to have multiple bone lesions in the cranial and pelvic bone and spine by CT scan. She also complained of frequent urination, excessive thirst and was referred to our hospital for further treatment.
Upon admission, physical examination showed increased deep tendon reflex on both upper and lower extremities, pain on movement of the neck. Exophthalmos, skin rashes and hepatosplenomegaly were not noted. The patient also denied recent body weight change or persistent fever. Blood analysis showed elevated eosinophil count and increased serum osmolality with decreased urine osmolality ( Table 1) . CT scan showed multiple bone lesions with a new lesion identified in the scapula. Bone scan was performed that showed consistent result with the multiple lytic bone lesions on CT scan. MRI showed atlantoaxial subluxation with enhancement of the surrounding soft tissue, and absent signal in the posterior pituitary gland on T1-weighted images (Fig. 4) . A diagnosis of DI was made.
Since the patient presented with pathological fracture of the cervical spine, she was initially treated with radiation of 10 Gy (2 Gy ×5) and subsequently with systemic chemotherapy according to the LCH-A1 protocol.
During the initial treatment, the patient developed grade 3 peripheral neuropathy, and vinblstine was omitted from subsequent treatment cycles. After six-weeks treatment with 6-MP and prednisone, her back pain decreased that enabled her to walk without support. Treatment was completed in approximately 6 months and she was off therapy at the end of March 2008. Radiologic examination at that time showed disappearance of the enhancing soft tissue mass around her cervical spine, with persistent bone lesions. Clinical symp- toms of DI were unchanged. She was assessed to have obtained NAD (no active disease) by the criteria of the Histiocyte Society. She has been followed up with no exacerbation of the disease until July 2010.
Discussion
There are several reports with a reasonably good number of patients on systemic treatment for LCH in children. DAL-HX83 and DAL-HX90 regimens consist of initial treatment with prednisone, vinblastine and etoposide, followed by continuous treatment with oral mercaptopurine and intermittent administration of prednisone, vinblastine, etoposide and methotrexate, according to disease risk. The initial response rate was 79% and the probability of reactivation of the disease was 36% at a median follow up of 7.5 years (11). LCH-I study was the first international randomized prospective study that compared the efficacy of vinblastine or etoposide and 53% of the patients were judged as responders. Reactivation of the disease was observed in 58% of the patients at a median of 9 months after achieving CR (12) . Comparing these results, the combination therapy seemed to yield a better response with respect to the rates of initial response and reactivation. Therefore, LCH-II was conducted that stratified the patients into high-risk and no-risk groups according to the extent of risk organ involvement (i. e. involvement of the liver, spleen, lung or hematopoietic system) and age. The high-risk group was randomized between initial treatment with the 2-(prednisone and vinblastine) or 3-(prednisone, etoposide and vinblastine) drug arm followed by continuation therapy with 6-MP and pulses of oral prednisone and vinblastine or the same regimen with the addition of etoposide, respectively. Patients in the norisk group were assigned initially to the 2 drugs and subsequently received continuation therapy without 6-MP. Response in the high-risk group improved to 67% compared to 43% in LCH-I. Mortality also decreased in this group with 44% in LCH-1 to 27% in LCH-II. Comparison between the 2-and 3-drug regimen in the high-risk group for LCH-II showed similar outcomes in terms of rapid response (2-drug vs 3-drug: 63%/71%), 5-year overall survival (74%/79%), disease reactivation rate (46%/46%) and the occurrence of permanent consequences (43%/37%). However, for those with risk organ involvement, mortality was reduced in the 3-drug regimen group with a hazard rate of 0.54 (95% CI = 0.29-1.00) (13) . LCH-III study is currently ongoing to solve the questions of whether longer treatment or more intense treatment would benefit certain risk patients using regimens including methotrexate. In contrast to children, treatment of LCH in adults has been challenging due to the small number of patients. Tsele et al treated three patients with LCH with etoposide alone (14) . All patients achieved clinical remission lasting for more than a year. Giona et al treated 11 patients with LCH according to their clinical presentation (8) . They were treated with either localized surgery or some kind of combined chemotherapy. Those who relapsed were treated with interferon. Altogether 5 patients remained in complete response at the time of last follow-up including those after salvage therapy. Saven and Burian conducted a phase II trial of cladribine, either at 0.1 mg/kg/day for 7 days by continuous intravenous infusion or 0.14 mg/kg/day over 2 hours intravenously for 5 consecutive days, repeated every 4 weeks (15) . Of the 12 evaluable patients, 7 had achieved complete responses and 2, partial response. Derenzini et al recently reported the efficacy of MACOP-B regimen in 7 adults with LCH (16) . The overall response rate was 100% with 57% of the patients remained in first CR with a median follow-up of 6.5 years. Although the number of patients enrolled was very small, it is plausible that a certain population of LCH in adults may benefit from intensive chemotherapy regimens.
Although it still remains to be elucidated whether previously identified poor risk factors such as the involvement of certain risk organs (liver, spleen, lung and hematopoietic system) at the time of diagnosis and response at 6 weeks of treatment would allow for patient stratification and therapy adjustment in pediatric patients, it needs to be determined whether these risk factors are applicable to adults as well. Treatment results of the present patients suggest that risk organ involvement may also be a good prognostic marker for adult patients. Also, Derenzini et al evaluated PET positivity in four patients, and identified PET negativity as a possible predicting factor for durable CR (16) . The number of pa- 
tients is still very limited, and further study is necessary to identify whether PET is useful to determine the duration of the treatment response.
In conclusion, we present the treatment outcome of two cases of adult LCH. Treatment with combination of cytotoxic drugs and prednisone as in LCH-A1 protocol seemed effective with long lasting remission in one case. Treatment of adult LCH needs further evaluation with identification of associated risk factors. International registration and clinical trials are clearly warranted in order to establish riskadjusted, optimal treatment.
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